News + Publications

Schematic of how interrupting ATPIF1 rescues cells with mitochondrial dysfunction

March 27, 2014

Scientists find potential target for treating mitochondrial disorders

Mitochondria, long known as “cellular power plants” for their generation of the key energy source adenosine triphosphate (ATP), are essential for proper cellular functions. Mitochondrial defects are often observed in a variety of diseases, including cancer, Alzheimer’s disease, and Parkinson’s disease, and are the hallmarks of a number of untreatable genetic mitochondrial disorders whose manifestations range from muscle weakness to organ failure. Whitehead Institute scientists have identified a protein whose inhibition could hold the key to alleviating suffering caused by such disorders.

Whitehead Institute and Biogen Idec logos

March 25, 2014

Whitehead Institute and Biogen Idec Initiate Discovery Research Collaboration

Whitehead Institute today announced it has entered into a scientific research collaboration with Biogen Idec aimed at driving early stage research that may lead to the development of novel therapies across a broad range of disease areas.

Diagram of the Nutrostat machine

March 16, 2014

How diabetes drugs may work against cancer

Scientists at Whitehead Institute have pinpointed a major mitochondrial pathway that imbues cancer cells with the ability to survive in low-glucose environments. By identifying cancer cells with defects in this pathway or with impaired glucose utilization, the scientists can predict which tumors will be sensitive to these anti-diabetic drugs known to inhibit this pathway.

Photo: Rudolf Jaenisch

March 10, 2014

Whitehead’s Jaenisch to receive prestigious Otto Warburg Medal

The German Society for Biochemistry and Molecular Biology (GBM) will present this year’s Otto Warburg Medal to Whitehead Institute Founding Member Rudolf Jaenisch later this month.

Graph of growth curves of wild type and amyloid-beta strains treated with clioquinol

March 3, 2014

Yeast model reveals Alzheimer’s drug candidate and its mechanism of action

Whitehead Institute scientists have used a yeast cell-based drug screen to identify a class of molecules that target the amyloid-β (Aβ) peptide involved in Alzheimer’s disease (AD).  

Paradigm Magazine


PDF

Past Issues

2012 Annual Report


PDF

Annual Report Archives

© Whitehead Institute for Biomedical Research         Nine Cambridge Center    Cambridge, MA 02142